JMP Securities Boosts Axon Enterprise (NASDAQ:AXON) Price Target to $430.00

Axon Enterprise (NASDAQ:AXON - Free Report) had its price target boosted by JMP Securities from $375.00 to $430.00 in a research report report published on Thursday, Marketbeat reports. They currently have an outperform rating on the biotechnology company's stock.

Several other research analysts also recently commented on AXON. Northland Securities raised their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an outperform rating in a research note on Thursday, August 8th. Barclays increased their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an overweight rating in a research note on Wednesday, August 7th. Jefferies Financial Group began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a buy rating and a $385.00 price target for the company. Craig Hallum increased their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a buy rating in a research report on Wednesday, August 7th. Finally, Robert W. Baird boosted their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an outperform rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $365.38.

Axon Enterprise Stock Up 6.3 %

Shares of Axon Enterprise stock traded up $22.80 on Thursday, hitting $384.51. The company had a trading volume of 973,638 shares, compared to its average volume of 520,782. The stock has a market capitalization of $29.02 billion, a price-to-earnings ratio of 112.43, a P/E/G ratio of 9.50 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. Axon Enterprise has a 1 year low of $189.12 and a 1 year high of $384.73. The stock has a 50 day moving average of $337.29 and a 200-day moving average of $313.60.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million for the quarter, compared to analysts' expectations of $478.35 million. During the same period last year, the business earned $0.80 EPS. The business's revenue was up 34.5% on a year-over-year basis. As a group, sell-side analysts forecast that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Activity at Axon Enterprise

In related news, CFO Brittany Bagley sold 4,338 shares of Axon Enterprise stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total value of $1,643,885.10. Following the transaction, the chief financial officer now owns 98,825 shares in the company, valued at approximately $37,449,733.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Matthew R. Mcbrady sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at $1,783,916.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brittany Bagley sold 4,338 shares of the company's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the sale, the chief financial officer now owns 98,825 shares of the company's stock, valued at $37,449,733.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 316,981 shares of company stock valued at $115,281,744. Insiders own 6.10% of the company's stock.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds have recently modified their holdings of AXON. ING Groep NV raised its holdings in shares of Axon Enterprise by 9.3% during the fourth quarter. ING Groep NV now owns 9,643 shares of the biotechnology company's stock valued at $2,491,000 after acquiring an additional 821 shares in the last quarter. Avantax Advisory Services Inc. grew its holdings in shares of Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company's stock valued at $1,659,000 after buying an additional 40 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Axon Enterprise during the first quarter valued at approximately $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Axon Enterprise by 14.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company's stock valued at $53,307,000 after buying an additional 22,013 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Axon Enterprise by 21.7% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company's stock valued at $2,693,000 after buying an additional 1,634 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.